BioMarin Pharmaceuticals (Novato, CA) is the first company to be quoted on SWX New Market (Zurich), the Swiss Exchange's new segment for high-tech growth companies. The company started trading on July 20, hoping to raise US$60 million by a dual listing, offering 1.8 million shares on the New Market and 2.7 million on Nasdaq. Although biotech firms have a reputation of being unstable and bad performers, "We're not in the business of beauty contests," says Swiss Exchange spokesperson Leo Hug, "if the candidate meets the listing criteria, it will be quoted." So far, no other companies have applied to list on the New Market, but Hug dismisses allegations that growth markets have lost their attraction.